VOR VS NKTX Stock Comparison

Performance

VOR
10/100

VOR returned -61.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

NKTX
10/100

NKTX returned -77.04% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

VOR
10/100

VOR receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

NKTX
79/100

NKTX receives a 78 of 100 based on 14 indicators. 10 are bullish, 2 are bearish.

Earnings

VOR
10/100

VOR has missed earnings 6 times in the last 20 quarters.

NKTX
10/100

NKTX has missed earnings 6 times in the last 20 quarters.

Profit

VOR
10/100

Out of the last 16 quarters, VOR has had 0 profitable quarters and has increased their profits year over year on 0 of them.

NKTX
10/100

Out of the last 19 quarters, NKTX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

VOR
43/100

VOR has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.

NKTX
33/100

NKTX has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

Sentiment

VOR

"Sentiment" not found for VOR

NKTX
69/100

NKTX had a bullish sentiment score of 68.55% across Twitter and StockTwits over the last 12 months. It had an average of 24.98 posts, 5.84 comments, and 31.47 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Vor Biopharma Inc. Common Stock Summary

Nasdaq / VOR

Healthcare

Biotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Nkarta, Inc. Common Stock Summary

Nasdaq / NKTX

Healthcare

Biotechnology

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Power up your portfolio